Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours
A single-agent dose escalating phase I and pharmacokinetic study with Cilengitide, an inhibitor of the integrins αvβ3 and αvβ5, was performed to determine its safety and toxicity. Cilengitide was administered as a one-hour infusion twice weekly without interruption to patients with histologically- o...
Saved in:
| Published in: | European journal of cancer (1990) Vol. 39; no. 7; pp. 917 - 926 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Oxford
Elsevier Ltd
01-05-2003
Elsevier |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | A single-agent dose escalating phase I and pharmacokinetic study with Cilengitide, an inhibitor of the integrins αvβ3 and αvβ5, was performed to determine its safety and toxicity. Cilengitide was administered as a one-hour infusion twice weekly without interruption to patients with histologically- or cytologically-confirmed metastatic solid tumours. Plasma pharmacokinetics were determined at days 1 and 15. 37 patients were enrolled into the study. Dose levels studied were 30, 60, 120, 180, 240, 400, 600, 850, 1200, and 1600 mg/m2/infusion. There was no dose-limiting toxicity (DLT). Pharmacokinetics were dose-independent and time-invariant. Apparent terminal half-life ranged from 3 to 5 h. At 120 mg/m2/infusion, peak plasma concentrations were attained that optimally inhibited tumour growth in preclinical models. Cilengitide can be safely administered using a continuous twice-weekly infusion regimen. As DLT was not reached, future trials should explore Cilengitide at different doses. |
|---|---|
| AbstractList | A single-agent dose escalating phase I and pharmacokinetic study with Cilengitide, an inhibitor of the integrins αvβ3 and αvβ5, was performed to determine its safety and toxicity. Cilengitide was administered as a one-hour infusion twice weekly without interruption to patients with histologically- or cytologically-confirmed metastatic solid tumours. Plasma pharmacokinetics were determined at days 1 and 15. 37 patients were enrolled into the study. Dose levels studied were 30, 60, 120, 180, 240, 400, 600, 850, 1200, and 1600 mg/m2/infusion. There was no dose-limiting toxicity (DLT). Pharmacokinetics were dose-independent and time-invariant. Apparent terminal half-life ranged from 3 to 5 h. At 120 mg/m2/infusion, peak plasma concentrations were attained that optimally inhibited tumour growth in preclinical models. Cilengitide can be safely administered using a continuous twice-weekly infusion regimen. As DLT was not reached, future trials should explore Cilengitide at different doses. |
| Author | Brindley, C Böttcher, S Drevs, J Eskens, F.A.L.M Dumez, H Wynendaele, W Hoekstra, R van Oosterom, A.T Perschl, A Verweij, J |
| Author_xml | – sequence: 1 givenname: F.A.L.M surname: Eskens fullname: Eskens, F.A.L.M email: f.eskens@erasmusmc.nl organization: Erasmus Medical Center, Department of Medical Oncology, PO Box 2040, 3000 CA Rotterdam, The Netherlands – sequence: 2 givenname: H surname: Dumez fullname: Dumez, H organization: University Hospital Gasthuisberg, 3000 Leuven, Belgium – sequence: 3 givenname: R surname: Hoekstra fullname: Hoekstra, R organization: Erasmus Medical Center, Department of Medical Oncology, PO Box 2040, 3000 CA Rotterdam, The Netherlands – sequence: 4 givenname: A surname: Perschl fullname: Perschl, A organization: Merck KGaA, D-64293 Darmstadt, Germany – sequence: 5 givenname: C surname: Brindley fullname: Brindley, C organization: Quintiles Scotland Limited, Edinburgh EH14 4AP, Scotland, UK – sequence: 6 givenname: S surname: Böttcher fullname: Böttcher, S organization: Merck KGaA, D-64293 Darmstadt, Germany – sequence: 7 givenname: W surname: Wynendaele fullname: Wynendaele, W organization: University Hospital Gasthuisberg, 3000 Leuven, Belgium – sequence: 8 givenname: J surname: Drevs fullname: Drevs, J organization: Tumour Biology Center, Freiburg, Germany – sequence: 9 givenname: J surname: Verweij fullname: Verweij, J organization: Erasmus Medical Center, Department of Medical Oncology, PO Box 2040, 3000 CA Rotterdam, The Netherlands – sequence: 10 givenname: A.T surname: van Oosterom fullname: van Oosterom, A.T organization: University Hospital Gasthuisberg, 3000 Leuven, Belgium |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14719190$$DView record in Pascal Francis |
| BookMark | eNqFUcFu1DAQjVCR2BY-AckXpFYiYCcxiU8ILW2pVAQScLYce9wMzdor28lqPws-pBJ_hLOL4MjJI897b-bNOy1OnHdQFM8ZfcUoe_P6CxVclB1txDmtLyilvC3Zo2LFulaUtOPVSbH6C3lSnMb4PYParqGr4tfnQUUgN0Q5Q7aDChul_T06SKhJTJPZE2-J9i6hm_wUSdqhBrIDuB_3BF0Kaga3NJTZoMOYPxJ6t7DWOIK7w4QGyPnlx_eEVUy0zcVLoojzM4yZP2CPyYcFngZYBOEuoIvk4cf88LM-rHUoee6RbdYGlyLZYRryxFk5DYZEP6Ihadr4KcSnxWOrxgjP_rxnxbery6_rD-Xtp-ub9bvbUle8SmWnrDW6620FAjivO9G0jeloVXOwVHdcq573lnHTG6MEM31rWw1V1fOuUbSvzwp-1NXBxxjAym3AjQp7yahccpGHXORydElrechFssx7ceRtVdRqtCF7wPiP3LRMMEEz7u0RB9nEjBBk1Nl89osBdJLG438m_Qa5I6vQ |
| CitedBy_id | crossref_primary_10_1111_j_1747_0285_2006_00356_x crossref_primary_10_1016_j_cub_2021_02_039 crossref_primary_10_1517_14728220802607363 crossref_primary_10_1097_JTO_0b013e318187220f crossref_primary_10_1200_JCO_2006_06_6514 crossref_primary_10_1021_bc900228m crossref_primary_10_1134_S1990750812030031 crossref_primary_10_1093_annonc_mdh930 crossref_primary_10_1002_chem_201503126 crossref_primary_10_1021_nn502690b crossref_primary_10_18097_pbmc20135903239 crossref_primary_10_1016_j_det_2007_06_005 crossref_primary_10_1016_j_str_2004_02_039 crossref_primary_10_1517_14728214_10_4_845 crossref_primary_10_1097_WCO_0b013e328332ba28 crossref_primary_10_1158_1078_0432_CCR_16_0623 crossref_primary_10_4103_ajns_AJNS_266_16 crossref_primary_10_2203_dose_response_09_049_Reynolds crossref_primary_10_1158_1535_7163_MCT_05_0120 crossref_primary_10_1172_JCI31791 crossref_primary_10_1182_blood_2004_08_3098 crossref_primary_10_1002_prp2_217 crossref_primary_10_1684_bdc_2011_1429 crossref_primary_10_1016_j_bbcan_2006_09_001 crossref_primary_10_1093_annonc_mdm140 crossref_primary_10_1038_cddis_2011_37 crossref_primary_10_1002_hep_23144 crossref_primary_10_1002_anie_201707948 crossref_primary_10_1002_cbic_201000062 crossref_primary_10_1007_s10637_010_9537_9 crossref_primary_10_1200_JCO_2009_26_6650 crossref_primary_10_1007_s00408_020_00400_y crossref_primary_10_1080_07357900701522638 crossref_primary_10_1016_j_mednuc_2015_12_002 crossref_primary_10_2217_fon_11_8 crossref_primary_10_3892_etm_00000037 crossref_primary_10_1016_j_nurt_2009_04_010 crossref_primary_10_1021_mp700073y crossref_primary_10_3390_cancers15041216 crossref_primary_10_3390_nano10020212 crossref_primary_10_1186_1471_2164_14_275 crossref_primary_10_1016_j_ejca_2005_02_017 crossref_primary_10_3390_cells10061450 crossref_primary_10_1002_ijc_21924 crossref_primary_10_1038_s41392_020_00436_9 crossref_primary_10_1158_1078_0432_CCR_06_2779 crossref_primary_10_1016_j_hoc_2004_09_010 crossref_primary_10_1016_S1470_2045_04_01565_7 crossref_primary_10_1016_j_cllc_2017_11_002 crossref_primary_10_1007_s11060_011_0650_1 crossref_primary_10_1016_j_biocel_2005_10_006 crossref_primary_10_1016_j_patbio_2004_11_003 crossref_primary_10_1038_nm_1941 crossref_primary_10_1080_10623320600698037 crossref_primary_10_1016_j_canlet_2006_03_012 crossref_primary_10_1016_j_urolonc_2007_03_017 crossref_primary_10_1158_1535_7163_MCT_08_0600 crossref_primary_10_1002_path_2803 crossref_primary_10_1002_ijc_24240 crossref_primary_10_1038_s41467_019_10871_0 crossref_primary_10_1038_ncpgasthep1097 crossref_primary_10_1200_JCO_2005_03_0841 crossref_primary_10_1200_JCO_2008_16_7510 crossref_primary_10_3390_cancers13071711 crossref_primary_10_1158_1078_0432_CCR_04_2623 crossref_primary_10_1177_107327480501200207 crossref_primary_10_1200_JCO_2007_14_1812 crossref_primary_10_1021_bm1012212 crossref_primary_10_1002_cncr_22273 crossref_primary_10_1007_s10637_010_9420_8 crossref_primary_10_1016_j_tips_2012_02_002 crossref_primary_10_1038_sj_bjc_6601401 crossref_primary_10_1007_s10989_010_9238_4 crossref_primary_10_1016_j_ejps_2017_05_016 crossref_primary_10_1161_ATVBAHA_108_172015 crossref_primary_10_2217_14796694_2_5_627 crossref_primary_10_1158_0008_5472_CAN_14_3761 crossref_primary_10_1517_14728222_2011_555402 crossref_primary_10_1016_j_compbiolchem_2019_05_008 crossref_primary_10_1039_b800533h crossref_primary_10_1634_theoncologist_2008_0272 crossref_primary_10_1155_2010_132641 crossref_primary_10_1517_13543780903336050 crossref_primary_10_1007_s00259_007_0497_z crossref_primary_10_1007_s11864_008_0052_6 crossref_primary_10_1586_ern_11_188 crossref_primary_10_1159_000151536 crossref_primary_10_1053_j_seminoncol_2007_09_009 crossref_primary_10_1517_17460441_2013_807248 crossref_primary_10_1016_j_biotechadv_2013_04_004 crossref_primary_10_1200_JCO_2005_02_194 crossref_primary_10_3390_cancers9090110 crossref_primary_10_1002_ange_201707948 crossref_primary_10_1158_1541_7786_MCR_18_0544 crossref_primary_10_1124_dmd_114_059295 crossref_primary_10_1007_s10585_007_9095_5 crossref_primary_10_4155_fmc_12_75 crossref_primary_10_1002_jcph_482 crossref_primary_10_1186_1479_5876_9_7 crossref_primary_10_2217_14796694_1_6_821 crossref_primary_10_1007_s12094_008_0183_z crossref_primary_10_1038_bjc_2011_152 crossref_primary_10_1186_2045_824X_3_7 crossref_primary_10_1007_s10354_006_0307_4 crossref_primary_10_1016_j_bbrc_2007_04_060 crossref_primary_10_1097_CMR_0b013e32835312e4 crossref_primary_10_1517_14656566_2014_947266 crossref_primary_10_1007_s11912_006_0043_3 crossref_primary_10_1016_j_yexcr_2015_07_018 crossref_primary_10_1517_13543784_12_12_1899 crossref_primary_10_1007_s10456_005_9026_5 crossref_primary_10_1159_000088826 crossref_primary_10_1186_1471_2407_6_285 crossref_primary_10_3390_cancers4041106 crossref_primary_10_1093_neuonc_not058 crossref_primary_10_1517_14728214_10_2_403 crossref_primary_10_1007_s10637_010_9573_5 crossref_primary_10_1016_j_molonc_2011_01_003 crossref_primary_10_1021_acsami_9b10830 crossref_primary_10_1186_s12885_016_2774_3 crossref_primary_10_2217_fon_13_9 crossref_primary_10_1016_j_bbadis_2021_166186 crossref_primary_10_1021_ac052078 crossref_primary_10_1002_ijc_27940 crossref_primary_10_1021_jm060233m crossref_primary_10_1161_CIRCRESAHA_113_302812 crossref_primary_10_1038_sj_bjc_6601576 crossref_primary_10_2176_nmc_ra2013_0200 crossref_primary_10_1007_s00259_010_1672_1 crossref_primary_10_1016_j_ceb_2008_06_007 crossref_primary_10_1002_jcph_343 crossref_primary_10_1007_s00761_006_1156_x crossref_primary_10_1117_1_1924696 crossref_primary_10_1007_s00761_011_2030_z crossref_primary_10_1007_s10555_013_9476_y crossref_primary_10_1002_pauz_200700243 crossref_primary_10_1517_13543784_17_8_1225 crossref_primary_10_1517_17460440902751581 crossref_primary_10_1002_ijc_20116 crossref_primary_10_2165_00148581_200709020_00002 crossref_primary_10_1002_jps_21286 crossref_primary_10_1002_med_20059 crossref_primary_10_1007_s10014_016_0261_9 crossref_primary_10_1007_s11523_010_0156_3 crossref_primary_10_1517_17425240903468696 crossref_primary_10_1200_JCO_2015_61_1525 crossref_primary_10_3390_cancers11050692 crossref_primary_10_1016_j_jocn_2004_03_004 crossref_primary_10_1182_blood_2006_05_023580 crossref_primary_10_1021_ja910544p crossref_primary_10_1586_14737159_6_4_613 crossref_primary_10_1002_bdrb_20232 crossref_primary_10_1016_j_bbcan_2005_09_003 crossref_primary_10_1016_j_prp_2022_153956 crossref_primary_10_1007_s10014_010_0007_z crossref_primary_10_1039_c0ib00013b crossref_primary_10_1074_jbc_M114_566802 crossref_primary_10_1007_s10549_011_1499_x |
| Cites_doi | 10.1200/JCO.2001.19.3.851 10.3109/15419069509081020 10.1038/bjc.1998.8 10.1126/science.270.5241.1500 10.1073/pnas.93.18.9764 10.1016/S1569-2558(08)60204-0 10.1006/mvre.1999.2179 10.1093/jnci/91.15.1281 10.1126/science.7512751 10.1016/S1040-8428(00)00055-X 10.1159/000024494 10.1073/pnas.84.18.6471 10.1023/A:1008377921886 10.1093/oxfordjournals.annonc.a010672 10.1200/JCO.2001.19.3.843 10.1177/009286159502900324 10.1002/(SICI)1097-0215(19970502)71:3<320::AID-IJC2>3.0.CO;2-# |
| ContentType | Journal Article |
| Copyright | 2003 Elsevier Science Ltd 2003 INIST-CNRS |
| Copyright_xml | – notice: 2003 Elsevier Science Ltd – notice: 2003 INIST-CNRS |
| DBID | IQODW AAYXX CITATION |
| DOI | 10.1016/S0959-8049(03)00057-1 |
| DatabaseName | Pascal-Francis CrossRef |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1879-0852 |
| EndPage | 926 |
| ExternalDocumentID | 10_1016_S0959_8049_03_00057_1 14719190 S0959804903000571 |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29G 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 6PF 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAWTL AAXUO ABBQC ABFNM ABGSF ABJNI ABLJU ABLVK ABMAC ABMZM ABOCM ABUDA ABXDB ABYKQ ACDAQ ACIUM ACPRK ACRLP ADBBV ADEZE ADMUD ADUVX AEBSH AEHWI AEKER AENEX AEVXI AFCTW AFFNX AFKWA AFRAH AFRHN AFTJW AFXIZ AGHFR AGRDE AGUBO AGYEJ AHHHB AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DOVZS DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IHE J1W K-O KOM LCYCR M29 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSU SSZ T5K UV1 WUQ X7M XPP Z5R ZA5 ZGI ZXP ~G- 08R AAUGY ABPIF ABPTK AKALU IQODW AAXKI AAYXX AFJKZ AKRWK CITATION |
| ID | FETCH-LOGICAL-c252t-8affdc8bf2e9e55389474d80235ef0c85cab5bf15dbdda91db7f7ce22b584a0b3 |
| ISSN | 0959-8049 |
| IngestDate | Thu Sep 26 18:43:38 EDT 2024 Sun Oct 22 16:08:01 EDT 2023 Fri Feb 23 02:33:53 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | Pharmacology Cilengitide (EMD 121974) Phase I clinical trial Angiogenesis inhibitor Integrins Antineoplastic agent Human Solid tumor Peptides Maximal dose Toxicity Inlegrins Treatment efficiency Chemotherapy Integrin Phase I trial Cilengitide Advanced stage Inhibitor Pharmacokinetics Therapeutic protocol |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c252t-8affdc8bf2e9e55389474d80235ef0c85cab5bf15dbdda91db7f7ce22b584a0b3 |
| PageCount | 10 |
| ParticipantIDs | crossref_primary_10_1016_S0959_8049_03_00057_1 pascalfrancis_primary_14719190 elsevier_sciencedirect_doi_10_1016_S0959_8049_03_00057_1 |
| PublicationCentury | 2000 |
| PublicationDate | May 2003 |
| PublicationDateYYYYMMDD | 2003-05-01 |
| PublicationDate_xml | – month: 05 year: 2003 text: May 2003 |
| PublicationDecade | 2000 |
| PublicationPlace | Oxford |
| PublicationPlace_xml | – name: Oxford |
| PublicationTitle | European journal of cancer (1990) |
| PublicationYear | 2003 |
| Publisher | Elsevier Ltd Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier |
| References | Gutheil, Campbell, Pierce (BIB20) 2000; 6 Hebbar, Revillion, Louchez, Fournier, Bonneterre, Peyrat (BIB15) 1999; 5 Gelmon, Eisenhauer, Harris, Ratain, Workman (BIB22) 1999; 91 Brooks, Clarke, Cheresh (BIB5) 1994; 264 Friedlander, Theesfeld, Sugita (BIB8) 1996; 93 Eskens, Verweij (BIB21) 2000; 34 Hayes, Huang, Mallah, Yang, Lippman, Li (BIB14) 1999; 58 Cheresh (BIB2) 1993; 6 Cutler, Sramek, Greenblatt, Chaikin, Collins (BIB18) 2000; 40 Cherish (BIB1) 1987; 84 Friedlander, Brooks, Shaffer, Kincaid, Varner, Cheresh (BIB6) 1995; 270 Wynendaele, Derua, Hoylaerts (BIB16) 1999; 10 Gordon, Margolin, Talpaz (BIB23) 2001; 19 Peters, Coogan, Berry (BIB13) 1998; 77 (BIB10) 1988 Li, Chen, Blystone, McHugh, Ross, Ramos (BIB7) 1998; 18 Margolin, Gordon, Holmgren (BIB24) 2001; 19 Gasparini, Brooks, Biganzoli (BIB9) 1998; 4 Gough, Hutchison, Keene (BIB12) 1995; 29 Varner, Brooks, Cheresh (BIB3) 1995; 3 Max, Gerritsen, Nooijen (BIB4) 1997; 71 (BIB11) 1979 Barleon, Siemeister, Martiny-Baron, Weindel, Herzog, Marme (BIB17) 1997; 57 Arbuck (BIB19) 1996; 7 (10.1016/S0959-8049(03)00057-1_BIB11) 1979 Gelmon (10.1016/S0959-8049(03)00057-1_BIB22) 1999; 91 (10.1016/S0959-8049(03)00057-1_BIB10) 1988 Gutheil (10.1016/S0959-8049(03)00057-1_BIB20) 2000; 6 Barleon (10.1016/S0959-8049(03)00057-1_BIB17) 1997; 57 Gasparini (10.1016/S0959-8049(03)00057-1_BIB9) 1998; 4 Friedlander (10.1016/S0959-8049(03)00057-1_BIB6) 1995; 270 Wynendaele (10.1016/S0959-8049(03)00057-1_BIB16) 1999; 10 Max (10.1016/S0959-8049(03)00057-1_BIB4) 1997; 71 Varner (10.1016/S0959-8049(03)00057-1_BIB3) 1995; 3 Friedlander (10.1016/S0959-8049(03)00057-1_BIB8) 1996; 93 Gough (10.1016/S0959-8049(03)00057-1_BIB12) 1995; 29 Peters (10.1016/S0959-8049(03)00057-1_BIB13) 1998; 77 Eskens (10.1016/S0959-8049(03)00057-1_BIB21) 2000; 34 Li (10.1016/S0959-8049(03)00057-1_BIB7) 1998; 18 Cherish (10.1016/S0959-8049(03)00057-1_BIB1) 1987; 84 Hayes (10.1016/S0959-8049(03)00057-1_BIB14) 1999; 58 Gordon (10.1016/S0959-8049(03)00057-1_BIB23) 2001; 19 Cutler (10.1016/S0959-8049(03)00057-1_BIB18) 2000; 40 Cheresh (10.1016/S0959-8049(03)00057-1_BIB2) 1993; 6 Arbuck (10.1016/S0959-8049(03)00057-1_BIB19) 1996; 7 Hebbar (10.1016/S0959-8049(03)00057-1_BIB15) 1999; 5 Margolin (10.1016/S0959-8049(03)00057-1_BIB24) 2001; 19 Brooks (10.1016/S0959-8049(03)00057-1_BIB5) 1994; 264 |
| References_xml | – volume: 71 start-page: 320 year: 1997 end-page: 324 ident: BIB4 article-title: Immunohistochemical analysis of integrin αvβ3 expression on tumour-associated vessels of human carcinomas publication-title: Int J Cancer contributor: fullname: Nooijen – volume: 84 start-page: 6471 year: 1987 end-page: 6475 ident: BIB1 article-title: Human endothelial cells synthesize and express an Arg-Gly-Asp directed adhesion receptor involved in attachment to fibrinogen and Van Willebrand factor publication-title: Proc Natl Acad Sci USA contributor: fullname: Cherish – volume: 19 start-page: 851 year: 2001 end-page: 856 ident: BIB24 article-title: Phase Ib trial of recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer publication-title: J Clin Oncol contributor: fullname: Holmgren – volume: 58 start-page: 224 year: 1999 end-page: 237 ident: BIB14 article-title: Angiopoeitin-1 and its receptor Tie-2 participate in the regulation of capillary-like tube formation and survival of endothelial cells publication-title: Microvasc Res. contributor: fullname: Li – volume: 7 start-page: 567 year: 1996 end-page: 573 ident: BIB19 article-title: Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996 publication-title: Ann Oncol contributor: fullname: Arbuck – volume: 4 start-page: 2625 year: 1998 end-page: 2634 ident: BIB9 article-title: Vascular integrin αvβ3 publication-title: Clin Cancer Res. contributor: fullname: Biganzoli – volume: 34 start-page: 83 year: 2000 end-page: 88 ident: BIB21 article-title: Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models publication-title: Crit Rev Oncol Hematol contributor: fullname: Verweij – volume: 29 start-page: 1039 year: 1995 end-page: 1048 ident: BIB12 article-title: Assessment of dose proportionality publication-title: Drug Inform J. contributor: fullname: Keene – volume: 18 start-page: 1 year: 1998 end-page: 14 ident: BIB7 article-title: Differential expression of αv integrins in K1735 melanoma cells publication-title: Invasion Metastasis contributor: fullname: Ramos – volume: 93 start-page: 9764 year: 1996 end-page: 9769 ident: BIB8 article-title: Involvement of integrins αvβ3 and αvβ5 in ocular neovascular diseases publication-title: Proc Natl Acad Sci USA contributor: fullname: Sugita – volume: 3 start-page: 367 year: 1995 end-page: 374 ident: BIB3 article-title: Review publication-title: Cell Adhes Comm. contributor: fullname: Cheresh – volume: 57 start-page: 5421 year: 1997 end-page: 5425 ident: BIB17 article-title: Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase (FLT-1) and a soluble form of FLT-1 in human vascular endothelial cells publication-title: Cancer Res. contributor: fullname: Marme – volume: 6 start-page: 225 year: 1993 end-page: 252 ident: BIB2 article-title: Integrins publication-title: Adv Mol Cell Biol. contributor: fullname: Cheresh – volume: 270 start-page: 1500 year: 1995 end-page: 1502 ident: BIB6 article-title: Definition of two angiogenic pathways by distinct αv integrins publication-title: Science contributor: fullname: Cheresh – volume: 91 start-page: 1281 year: 1999 end-page: 1287 ident: BIB22 article-title: Anticancer agents targeting signaling molecules and cancer cell environment publication-title: J Natl Cancer Inst. contributor: fullname: Workman – volume: 19 start-page: 843 year: 2001 end-page: 850 ident: BIB23 article-title: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer publication-title: J Clin Oncol contributor: fullname: Talpaz – volume: 264 start-page: 569 year: 1994 end-page: 571 ident: BIB5 article-title: Requirement of vascular integrin αvβ3 for angiogenesis publication-title: Science contributor: fullname: Cheresh – year: 1979 ident: BIB11 article-title: WHO Handbook for Reporting Results of Cancer Treatment. Offset Publication No. 40 – volume: 10 start-page: 965 year: 1999 end-page: 971 ident: BIB16 article-title: Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers publication-title: Ann Oncol contributor: fullname: Hoylaerts – volume: 6 start-page: 3056 year: 2000 end-page: 3061 ident: BIB20 article-title: Targeted antiangiogenic therapy for cancer using Vitaxin publication-title: Clin Cancer Res. contributor: fullname: Pierce – volume: 5 start-page: 1427 year: 1999 end-page: 1433 ident: BIB15 article-title: Prognostic value of circulating soluble E-selectin concentrations in node-negative breast cancer patients publication-title: Clin Cancer Res. contributor: fullname: Peyrat – volume: 77 start-page: 51 year: 1998 end-page: 56 ident: BIB13 article-title: Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis publication-title: Br J Cancer contributor: fullname: Berry – year: 1988 ident: BIB10 article-title: Guidelines for Reporting of Adverse Drug Reactions – volume: 40 start-page: 1183 year: 2000 end-page: 1204 ident: BIB18 article-title: Defining the maximum tolerated dose publication-title: J Clin Pharmacol. contributor: fullname: Collins – year: 1988 ident: 10.1016/S0959-8049(03)00057-1_BIB10 – volume: 6 start-page: 3056 year: 2000 ident: 10.1016/S0959-8049(03)00057-1_BIB20 article-title: Targeted antiangiogenic therapy for cancer using Vitaxin publication-title: Clin Cancer Res. contributor: fullname: Gutheil – volume: 19 start-page: 851 year: 2001 ident: 10.1016/S0959-8049(03)00057-1_BIB24 article-title: Phase Ib trial of recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2001.19.3.851 contributor: fullname: Margolin – volume: 4 start-page: 2625 year: 1998 ident: 10.1016/S0959-8049(03)00057-1_BIB9 article-title: Vascular integrin αvβ3 publication-title: Clin Cancer Res. contributor: fullname: Gasparini – volume: 3 start-page: 367 year: 1995 ident: 10.1016/S0959-8049(03)00057-1_BIB3 article-title: Review publication-title: Cell Adhes Comm. doi: 10.3109/15419069509081020 contributor: fullname: Varner – volume: 57 start-page: 5421 year: 1997 ident: 10.1016/S0959-8049(03)00057-1_BIB17 article-title: Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase (FLT-1) and a soluble form of FLT-1 in human vascular endothelial cells publication-title: Cancer Res. contributor: fullname: Barleon – volume: 77 start-page: 51 year: 1998 ident: 10.1016/S0959-8049(03)00057-1_BIB13 article-title: Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis publication-title: Br J Cancer doi: 10.1038/bjc.1998.8 contributor: fullname: Peters – volume: 270 start-page: 1500 year: 1995 ident: 10.1016/S0959-8049(03)00057-1_BIB6 article-title: Definition of two angiogenic pathways by distinct αv integrins publication-title: Science doi: 10.1126/science.270.5241.1500 contributor: fullname: Friedlander – volume: 93 start-page: 9764 year: 1996 ident: 10.1016/S0959-8049(03)00057-1_BIB8 article-title: Involvement of integrins αvβ3 and αvβ5 in ocular neovascular diseases publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.93.18.9764 contributor: fullname: Friedlander – volume: 5 start-page: 1427 year: 1999 ident: 10.1016/S0959-8049(03)00057-1_BIB15 article-title: Prognostic value of circulating soluble E-selectin concentrations in node-negative breast cancer patients publication-title: Clin Cancer Res. contributor: fullname: Hebbar – volume: 40 start-page: 1183 year: 2000 ident: 10.1016/S0959-8049(03)00057-1_BIB18 article-title: Defining the maximum tolerated dose publication-title: J Clin Pharmacol. contributor: fullname: Cutler – volume: 6 start-page: 225 year: 1993 ident: 10.1016/S0959-8049(03)00057-1_BIB2 article-title: Integrins publication-title: Adv Mol Cell Biol. doi: 10.1016/S1569-2558(08)60204-0 contributor: fullname: Cheresh – volume: 58 start-page: 224 year: 1999 ident: 10.1016/S0959-8049(03)00057-1_BIB14 article-title: Angiopoeitin-1 and its receptor Tie-2 participate in the regulation of capillary-like tube formation and survival of endothelial cells publication-title: Microvasc Res. doi: 10.1006/mvre.1999.2179 contributor: fullname: Hayes – volume: 91 start-page: 1281 year: 1999 ident: 10.1016/S0959-8049(03)00057-1_BIB22 article-title: Anticancer agents targeting signaling molecules and cancer cell environment publication-title: J Natl Cancer Inst. doi: 10.1093/jnci/91.15.1281 contributor: fullname: Gelmon – volume: 264 start-page: 569 year: 1994 ident: 10.1016/S0959-8049(03)00057-1_BIB5 article-title: Requirement of vascular integrin αvβ3 for angiogenesis publication-title: Science doi: 10.1126/science.7512751 contributor: fullname: Brooks – volume: 34 start-page: 83 year: 2000 ident: 10.1016/S0959-8049(03)00057-1_BIB21 article-title: Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models publication-title: Crit Rev Oncol Hematol doi: 10.1016/S1040-8428(00)00055-X contributor: fullname: Eskens – volume: 18 start-page: 1 year: 1998 ident: 10.1016/S0959-8049(03)00057-1_BIB7 article-title: Differential expression of αv integrins in K1735 melanoma cells publication-title: Invasion Metastasis doi: 10.1159/000024494 contributor: fullname: Li – volume: 84 start-page: 6471 year: 1987 ident: 10.1016/S0959-8049(03)00057-1_BIB1 article-title: Human endothelial cells synthesize and express an Arg-Gly-Asp directed adhesion receptor involved in attachment to fibrinogen and Van Willebrand factor publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.84.18.6471 contributor: fullname: Cherish – year: 1979 ident: 10.1016/S0959-8049(03)00057-1_BIB11 – volume: 10 start-page: 965 year: 1999 ident: 10.1016/S0959-8049(03)00057-1_BIB16 article-title: Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers publication-title: Ann Oncol doi: 10.1023/A:1008377921886 contributor: fullname: Wynendaele – volume: 7 start-page: 567 year: 1996 ident: 10.1016/S0959-8049(03)00057-1_BIB19 article-title: Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996 publication-title: Ann Oncol doi: 10.1093/oxfordjournals.annonc.a010672 contributor: fullname: Arbuck – volume: 19 start-page: 843 year: 2001 ident: 10.1016/S0959-8049(03)00057-1_BIB23 article-title: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2001.19.3.843 contributor: fullname: Gordon – volume: 29 start-page: 1039 year: 1995 ident: 10.1016/S0959-8049(03)00057-1_BIB12 article-title: Assessment of dose proportionality publication-title: Drug Inform J. doi: 10.1177/009286159502900324 contributor: fullname: Gough – volume: 71 start-page: 320 year: 1997 ident: 10.1016/S0959-8049(03)00057-1_BIB4 article-title: Immunohistochemical analysis of integrin αvβ3 expression on tumour-associated vessels of human carcinomas publication-title: Int J Cancer doi: 10.1002/(SICI)1097-0215(19970502)71:3<320::AID-IJC2>3.0.CO;2-# contributor: fullname: Max |
| SSID | ssj0007840 |
| Score | 2.2608466 |
| Snippet | A single-agent dose escalating phase I and pharmacokinetic study with Cilengitide, an inhibitor of the integrins αvβ3 and αvβ5, was performed to determine its... |
| SourceID | crossref pascalfrancis elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 917 |
| SubjectTerms | Angiogenesis inhibitor Antineoplastic agents Biological and medical sciences Chemotherapy Cilengitide (EMD 121974) Integrins Medical sciences Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Pharmacology Pharmacology. Drug treatments Phase I clinical trial Tumors |
| Title | Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours |
| URI | https://dx.doi.org/10.1016/S0959-8049(03)00057-1 |
| Volume | 39 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Za9tAEF5yQCmU0pOmR5iHGhJUOdZKqqRHN1GoS1MKSSFvYqVdYeHWDr4C_VftDwn0H3X2kFZKCT2gL7JYr3ZlzaeZ2fHMt4S8jChlXlBSt_QpdwOaBy5DK-jG3Oc88QruF2oT29Pow3l8lAbpxmZdrG7b_quksQ1lLStn_0LazaDYgOcoczyi1PH4R3L_OEa75Iw0AYDhpZ6gKymJWRc1g7RMUK-mK5n-urxEVeFcKmJ9SR4htyNStK2sQ6ur0jYque1Ktay4ckzTkyPHQ1UUBT2aqCxQZzpbC0niMa5y1BTzOgFBc1LIZJzeYdp7463VB_XVTXaaQsdyvdaFd3WWAj63ijvL1Rd8DIsb_1Ew3nUhr5krGiq0hK14R7qYCL12OO4P--_7NlaPWvrrtXINMZG_v5NXKUsGivFnGwauQyatBEUdx6treWziVBMQHWgC1b7Q5iCOEhed0o690ORL5r2IWso_0VWoxo9INBPALyZKR0tOm-l6cn8wfAzSe45cz9rlJltS9ZVdUSHLTrjY36aoV1Gtbw9H6fm7xvWIYlUB3IxtS9YO7IR7A3_fTHaTM3bngi1QRZR6b5eWw3V2j9w1KyUYaojfJxti-oDcOjG5IA_JD4V0GAGCCK4hHRTSYVaCRToopINGOrSQDl2ky6taSIc9xDlonO-_AgYK49BgXHZHjEODcbj6tr767qvbUqchfgc1pkFiGmpMg8I0GEw_Ip-O07PDt67ZoMQtaEiXbszKkhdxXlKRiBBdhySIAi4pFUNRDoo4LFge5qUX8pxzlng8j8qoEJTm6PazQe4_JlvT2VQ8ISA5obyQCeazMMhDPxeBeF0wIYTHkpKxHdKvJZVdaB6azCZoomgzKdps4GdKtJm3Q-JanplxprWTnCEQf3fpbkf-dkL0ZBNcQTz997Gfkdv2jXxOtpbzlXhBNhd8tWvA_BO7e_e5 |
| link.rule.ids | 315,782,786,27933,27934 |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phase+I+and+pharmacokinetic+study+of+continuous+twice+weekly+intravenous+administration+of+Cilengitide+%28EMD+121974%29%2C+a+novel+inhibitor+of+the+integrins+%CE%B1v%CE%B23+and+%CE%B1v%CE%B25+in+patients+with+advanced+solid+tumours&rft.jtitle=European+journal+of+cancer+%281990%29&rft.au=Eskens%2C+F.A.L.M&rft.au=Dumez%2C+H&rft.au=Hoekstra%2C+R&rft.au=Perschl%2C+A&rft.date=2003-05-01&rft.pub=Elsevier+Ltd&rft.issn=0959-8049&rft.eissn=1879-0852&rft.volume=39&rft.issue=7&rft.spage=917&rft.epage=926&rft_id=info:doi/10.1016%2FS0959-8049%2803%2900057-1&rft.externalDocID=S0959804903000571 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0959-8049&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0959-8049&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0959-8049&client=summon |